廣譽遠(600771.SH):控股子公司擬申請授信額度1.3億元
格隆匯3月18日丨廣譽遠(600771.SH)公佈,公司第七屆董事會第二次會議召開,經會議認真審議,通過了《公司關於為控股子公司申請銀行綜合授信提供擔保的議案》。
為進一步拓寬融資渠道,提高資金管理水平,公司控股子公司山西廣譽遠國藥有限公司根據其生產經營和業務發展的需要,擬分別向晉中銀行股份有限公司太谷支行和中國銀行股份有限公司太原漪汾支行申請總額不超過3000萬元和1億元的綜合授信額度,擬申請的授信額度合計為1.3億元。公司擬為其向上述銀行申請的綜合授信提供連帶責任保證,並授權董事長在上述擔保額度內代表公司辦理相關手續,簽署相關法律文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.